<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03121638</url>
  </required_header>
  <id_info>
    <org_study_id>NBP608_VZ_I_2012</org_study_id>
    <nct_id>NCT03121638</nct_id>
  </id_info>
  <brief_title>Safety Study of NBP608 in Healthy Adult Volunteers</brief_title>
  <official_title>An Open Label, Active Controlled, Parallel Group Phase I Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of NBP608 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Indication: Protection against varicella and herpes zoster

        -  Study Objectives

             -  Primary: Safety and tolerability assessment after single dose administration of
                NBP608

             -  Secondary: immunogenicity assessment after single dose administration of NBP608
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open label, active controlled, dose-escalation, parallel group study
      to assess the safety, tolerability and immunogenicity of NBP608 in healthy adult volunteers.
      Total of 150 healthy subjects aged 20 and over are enrolled, and each subject is administered
      with single dose of vaccine which is sequentially assigned to active group 1, 2 and study
      group 1~3 in 1:1:1:1:1 ratio(30 subjects are enrolled at each groups) .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Rate of Adverse Event</measure>
    <time_frame>42days after Investigation Product Vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Varicella Zoster Virus Antibody Titer Measured by FAMA(Fluorescent Antibody to Membrane Antigen)</measure>
    <time_frame>42days after Investigation Product Vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Varicella Zoster Virus Antibody Titer Measured by gpELISA(Glycoprotein Enzyme-Linked Immunosorbent Assay)</measure>
    <time_frame>42days after Investigation Product Vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Varicella Zoster</condition>
  <condition>Immunization; Infection</condition>
  <arm_group>
    <arm_group_label>VARIVAX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZOSTAVAX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NBP6081</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NBP6082</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NBP6083</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VARIVAX</intervention_name>
    <description>Preparation of Oka/Merck strain of live, attenuated varicella zoster virus</description>
    <arm_group_label>VARIVAX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ZOSTAVAX</intervention_name>
    <description>Preparation of Oka/Merck strain of live, attenuated varicella zoster virus</description>
    <arm_group_label>ZOSTAVAX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NBP6081</intervention_name>
    <description>Preparation of Oka/SK strain of live, attenuated varicella zoster virus</description>
    <arm_group_label>NBP6081</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NBP6082</intervention_name>
    <description>Preparation of Oka/SK strain of live, attenuated varicella zoster virus</description>
    <arm_group_label>NBP6082</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NBP6083</intervention_name>
    <description>Preparation of Oka/SK strain of live, attenuated varicella zoster virus</description>
    <arm_group_label>NBP6083</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults aged 20 and over

          -  Availability to volunteer for the entire study duration and willing to adhere to all
             protocol requirements

          -  Female subjects of post-menopausal (amenorrhea for 24 months) whose pregnancy tests
             was found negative at screening visit

          -  Subjects of seropositive for Varicella-Zoster virus at screening visit

        Exclusion Criteria:

          -  Patients with herpes zoster

          -  Subjects with a history of vaccination for herpes zoster

          -  Pregnant or lactating women

          -  Participants in another clinical study within 4 weeks before vaccination in this
             study, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee-jin Cheong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Varicella Vaccine</keyword>
  <keyword>Herpes Zoster Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

